Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02263885 · ClinicalTrials.gov registry record · NA
ExAblate Transcranial MRgFUS of the Globus Pallidum for Treatment of Parkinson's Disease
A NA study, sponsored by InSightec.
- Completed
- Registry status
- NA
- Development phase
- 20
- Enrollment target
NCT02263885 is a NA study that has completed, run by InSightec. The registered enrollment target is 20 participants.
The verdict
NCT02263885, a NA study, has completed, sponsored by InSightec.
- COMPLETED
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
Study Summary
The proposed study will evaluate the safety, and initial efficacy of using the ExAblate Transcranial to create a unilateral lesion in the globus pallidus as an adjunct to PD medications in subjects who are over 30 years of age and considered medication-refractory with advanced idiopathic Parkinson's disease (PD).
Interventions
- DEVICE ExAblate Transcranial System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2015-04 |
| Est. Completion | 2019-07-26 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02263885
The ClinicalTrials.gov registry entry for NCT02263885 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is InSightec, which has 38 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ExAblate Transcranial System is the first listed.
NCT02263885 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02263885 about?
NCT02263885 is a clinical study titled "ExAblate Transcranial MRgFUS of the Globus Pallidum for Treatment of Parkinson's Disease". The proposed study will evaluate the safety, and initial efficacy of using the ExAblate Transcranial to create a unilateral lesion in the globus pallidus as an adjunct to PD medications in subjects who are over 30 years of age and considered medication-refractory with advanced idiopathic Parkinson's...
What is the current status of trial NCT02263885?
This trial is currently completed. It is a NA study. The enrollment target is 20 participants. The study started on 2015-04. Estimated completion is 2019-07-26.
What interventions are being tested in trial NCT02263885?
The interventions under investigation include: ExAblate Transcranial System (DEVICE).
Who is sponsoring clinical trial NCT02263885?
This trial is sponsored by InSightec, which has 38 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.